Sign in
Taking people in United StatesPhase 4

PPI Dosing Per CYP2C19 Genotype

Key facts

Who runs it
University of Florida
Where
Jacksonville, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
200 people, planned
Started
1 Nov 2026
Expected to end
1 Apr 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CYP2C19 based dosing Proton Pump Inhibitors
  • Conventional proton pump inhibitor dose
Record updated
12 November 2026

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • age ≥ 18 years
  • diagnosis of Gastroesophageal Reflux Disease (GERD) scheduled for an esophagogastroduodenoscopy (EGD)
  • patients diagnosed with Erosive Esophagitis on endoscopy (EGD)

Who cannot take part

  • diagnosed with non-erosive reflux disease (NERD)
  • age <18 years
  • pregnancy

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 90 years old?

This trial is currently available in United States.

  • UF HealthJacksonville, United StatesContact: Ruchir Puri, MDTaking people

About the trial

What the trial wants to find out

This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.

The 2 groups in the trial

  • InterventionTreatment being tested

    proton pump inhibitor dose based on CYP2C19 phenotypes

    Treatment: CYP2C19 based dosing Proton Pump Inhibitors

  • ControlExisting treatment, for comparison

    conventional proton pump inhibitor dose of Pantoprazole 40 mg once or twice daily

    Treatment: Conventional proton pump inhibitor dose

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study to Assess Healing of Erosive Esophagitis in Patients Randomized to Conventional PPI Doses Versus Dosing Based on CYP2C19 Genotype
Criteria questions
Built from NCT07843264, who can take part
Record updated
12 November 2026